Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAkers Biosciences Inc. Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Result of AGM

Tue, 4th Nov 2014 16:49

RNS Number : 1490W
Akers Biosciences, Inc.
04 November 2014


For immediate release: 04 November 2014

Akers Biosciences, Inc.

Result of AGM

Akers Biosciences, Inc. (Nasdaq: AKER) (LSE: AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, is pleased to announce that all resolutions proposed at the Annual General Meeting of the Company, held earlier today, were duly passed.


Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

For more information:

Raymond F. Akers, Jr. PhD

Executive Chairman of the Board

Akers Biosciences, Inc.

Tel. +1 856 848 8698

Twitter. @AkersBio

Geoff Nash / Scott Mathieson (Corporate Finance)

Steve Norcross (Broking)

finnCap (Nomad and Broker)

Tel. +44 (0)20 7220 0500

Ben Simons / Alexandra Roper

Vigo Communications (UK Investor Relations)

Tel. +44 (0)20 7016 9570

Email. akers@vigocomms.com

This information is provided by RNS
The company news service from the London Stock Exchange

Login to your account

Don't have an account? Click here to register.